Singapore markets closed

Straits Times Index
3,130.24
+15.16(+0.49%)
Nikkei
25,937.21
-484.84(-1.83%)
Hang Seng
17,222.83
+56.96(+0.33%)
FTSE 100
6,893.81
+12.22(+0.18%)
BTC-USD
19,277.51
-411.60(-2.09%)
CMC Crypto 200
443.49
+0.06(+0.01%)

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

3.0900

+0.1000

(+3.34%)

At close: 04:00PM EDT

3.1100

+0.02

(+0.65%)

After hours:

07:13PM EDT

Loading interactive chart…

Motley Fool
MannKind Corporation (MNKD) Q2 2022 Earnings Call Transcript
As a reminder, this call is being recorded on August 9, 2022, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call until August 23, 2022. Joining us today from MannKind are Chief Executive Officer Michael Castagna and Chief Financial Officer Steven Binder.
Zacks
MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Motley Fool
Why Shares of MannKind Corporation Climbed 10.4% on Monday
What happened Shares of MannKind Corporation (NASDAQ: MNKD), a biotech company that specializes in finding therapies for endocrine and orphan lung diseases, rose 10.4% on Monday. The stock closed at $3.